NSEDisclosure under SEBI Takeover Regulations29 Jun 2026 · 29 Jun 2026, 07:45 pm
Disclosure under SEBI Takeover Regulations
Piramal Pharma Limited · PPLPHARMA
✦ AI SummaryPromoter Reclassif.
Piramal Pharma Limited's promoter, Ajay G. Piramal, has submitted a declaration under SEBI Takeover Regulations stating that the promoter group has not made any encumbrance on the company's shares during the financial year 2025-2026.
Analysis Scores
Earnings Impact1/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact1/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Ajay G. Piramal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Attachments (1)
📄pdf
Download →
team_sandeshc_11052026115720_39.pdf
View document text
Ajay G. Piramal
Date: 6th April, 2026
To, To,
BSE Limited National Stock Exchange of India Limited
Mumbai Mumbai
BSE Script code: 543635 NSE Symbol: PPLPHARMA
Re.: Piramal Pharma Limited
Sub: Declaration under Regulation 31(4) of SEBI (SAST) Regulations, 2011 from the
Promoter
Pursuant to the Regulation 31(4) of Securities and Exchange Board of India (Substantial
Acquisition of Shares and Takeovers) Regulations, 2011 (“SEBI SAST”), we hereby declare that
the Promoters or the Promoter Group have not made any encumbrance, directly or indirectly, on
the shares / securities of the Company ‘Piramal Pharma Limited’ during the financial year 2025-
2026.
You are requested to take note of the above.
Thanking you,
Yours faithfully
For and on behalf of Promoter and Promoter Group
Ajay G. Piramal